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ABSTRACT
Background: Clinical trials provide evidence of the high effectiveness of
Helicobacter pylori eradication for preventing recurrent ulcer-related gas-
trointestinal hemorrhage. The best strategy for curing the infection in this
setting is, however, still under debate.
Objective: To evaluate four different strategies for prevention of rebleed-
ing in patients with peptic ulcer hemorrhage: 1) test for H. pylori and
treatment, if positive; 2) proton pump inhibitor maintenance; 3) no pre-
ventive treatment; 4) empirical H. pylori eradication immediately after
bleeding.
Methods: A decision analysis model was used, with a time horizon of
2 years and a third-party payer perspective. Costs were estimated for two
different settings: a low-cost-for-care area (Spain) and a high-cost area
(USA). Main outcome measure was incremental cost-effectiveness ratio for
each upper gastrointestinal hemorrhage avoided.
Results: Empirical H. pylori eradication was the dominant strategy: its
estimated rate of recurrent bleeding was lower (6.1%) than those of
strategies 1 (7.4%), 2 (11.1%), and 3 (18.4%) and it was the least
expensive strategy. The results remained stable when variables were
changed inside a wide range of plausible values. Sensitivity analysis also
showed that the prevalence of H. pylori in bleeding ulcer was the variable
that most inﬂuenced the results: when it was below 45% in Spain or below
51% in the United States, empirical eradication was not a dominant
strategy although it remained cost-effective.
Conclusion: In patients with bleeding peptic ulcer, empirical treatment of
H. pylori infection immediately after feeding is restarted is the most
cost-effective strategy for preventing recurrent hemorrhage.
Keywords: bleeding peptic ulcer, cost-effectiveness, Helicobacter pylori,
prevention, treatment.
Introduction
Hemorrhage is the most frequent complication of peptic ulcer
disease and is associated with substantial morbidity, mortality,
and costs [1]. Helicobacter pylori eradication is the most efﬁca-
cious measure for preventing recurrence in infected patients [2].
Current guidelines differ in terms of how and when the H. pylori
treatment should be performed [3,4]. Some guidelines even
encourage empirical eradication therapy [3].
The rationale for empirical eradication is based on three facts.
First, the prevalence of H. pylori infection in peptic ulcer bleed-
ing is over 90% in our environment [5]. Second, the sensitivity
of diagnostic techniques for H. pylori infection falls markedly
during bleeding [5]. Finally, histology ﬁndings are often unavail-
able at discharge and, in clinical practice studies, more than 50%
of bleeding patients were lost to follow-up without receiving
treatment [6].
Empirical eradication treatment before discharge is likely to
improve compliance. Nevertheless, there are no clinical data to
support empirical treatment, and the pharmacoeconomic data are
controversial. Sharma et al. [7] reported that testing and treating
H. pylori wasmore cost-effective than ulcer healing for preventing
recurrent hemorrhage, but their study did not analyze empiri-
cal H. pylori treatment. Ghoshal et al. [8] found that empirical
treatment of H. pylori infection was the most cost-effective strat-
egy. The study was, however, restricted to duodenal ulcer patients
and did not consider losses to follow-up in the analysis. Finally,
Ofman et al. [9] found that the most cost-effective strategy in
bleeding patients was to investigate and treat H. pylori eradication
in those infected, and maintenance with histamine-2 receptor
antagonist in noninfected patients. This ﬁnding is based, however,
on the assumption of 1) a very high prevalence of “idiopathic”
ulcers related neither to H. pylori nor to nonsteroidal antiinﬂam-
matory drugs (NSAIDs) and 2) a very high bleeding relapse rate in
this group of “idiopathic” ulcers. These assumptions could not be
true as most studies reporting a low prevalence of H. pylori
infection in bleeding ulcer used only endoscopic tests (usually
histology, urease test, or the combination of both) obtained at the
moment of the hemorrhage [10], an approach that is known to
underestimate the prevalence of the infection [5]. Moreover,
studies do not consider losses to follow-up in the analysis [7–9].
Wide geographical differences in costs and in the prevalence
of H. pylori in bleeding ulcers may also inﬂuence cost-
effectiveness. For this reason, the present study was designed to
provide calculations for two different settings: 1) a setting with a
low cost for care and high H. pylori prevalence—the Catalonian
Public Health Service, and 2) a high-cost-for-care area with (pos-
sibly) a low H. pylori prevalence—the United States.
The objective of the present study was to compare four dif-
ferent strategies to prevent recurrence in patients with bleeding
peptic ulcer: 1) test for H. pylori and treatment, if positive; 2)
proton pump inhibitor (PPI) maintenance; 3) no preventive treat-
ment as a control branch; and 4) empirical H. pylori eradication.
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Material and Methods
A decision analytic model was used. A detailed description of
methodology can be found online at the ISPOR Web site.
Patient Population
The population of the study included patients hospitalized with
hemorrhage due to peptic ulcer disease.
Perspectives and Time Horizon
The perspective was those of a third-party payer—the National
Health Service in the case of Catalonia (Spain), and a health
insurer in the case of the United States. The time horizon was
2 years.
Decision Model
Analysis was performed by using a decision tree (Fig. 1). Four
initial strategies were analyzed: 1) test for H. pylori and treat-
ment, if positive; 2) PPI maintenance; 3) no preventive treatment;
and 4) empirical H. pylori eradication. NSAID cotherapy and
losses to follow-up were considered in all strategies. In the four
strategies, patients underwent emergency endoscopy.
In the ﬁrst strategy, which is currently in use in most centers,
H. pylori infection was investigated by histology. After resolution
of the bleeding, patients were attended on an outpatient basis. A
negative initial histology result was interpreted as a probable
false negative [5] and was followed by a 13C-urea breath test
(UBT). If subsequent UBT were negative, maintenance PPI
therapy was indicated. Patients with a positive H. pylori histol-
ogy or UBT were prescribed triple therapy. Diagnosis of H. pylori
after treatment was performed with a UBT except for gastric
ulcers in which endoscopy and histology were performed to rule
out malignancy. Treatment failures received quadruple rescue
therapy. In patients in whom a second H. pylori treatment was
unsuccessful, maintenance PPI treatment was administered.
In strategies 2 and 3, healing therapy with PPI once daily for
8 weeks was prescribed. After this, only patients with gastric
ulcer underwent endoscopy. No testing for H. pylori or eradica-
tion treatment was performed. In the PPI maintenance strategy,
all patients were prescribed long-term maintenance PPI. In the
“no preventive treatment” strategy, patients did not receive
further treatment.
Finally, in the “empirical H. pylori eradication” strategy, no
test for H. pylori was performed after initial endoscopy. Triple
therapy was initiated before discharge, as soon as the patient
tolerated oral intake. Subsequent follow-up was similar to those
of the test-and-treat strategy.
Attempts to discontinue NSAID therapy and long-term PPI
prophylaxis in patients requiring continued anti-inﬂammatory
drugs were performed in all strategies.
Probabilities and Costs
Probability values and ranges used in the sensitivity analysis were
taken from the medical literature. For the low-cost area, we
obtained cost data mainly from the Catalonian Public Health
Service [11]. Costs were expressed in euros (€). For the high-cost
area, US dollars were used as a monetary unit ($1.4 = €1,
approximately). US costs were obtained from previous cost-
effectiveness articles. Because of the lack of primary and second-
ary information, indirect costs were not included. Data for major
baseline assumptions and costs along with a detailed description
of methodology are available online.
Analysis
The primary evaluation variable was avoidance of recurrent
bleeding. Incremental cost-effectiveness ratio (ICER) for upper
gastrointestinal hemorrhage avoided was calculated. Mortality
was calculated as a secondary variable. All calculations were
performed using conventional software (Microsoft Excel XP).
One-way sensitivity and multiple-way probabilistic analyses
using Monte Carlo simulation for Microsoft Excel XP sensitivity
analyses were performed.
Figure 1 Decision tree used in the study, identifying decision alternatives. H. pylori, Helicobacter pylori; PPI, proton pump inhibitor; UBT, urea breath test.
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Results
The baseline analysis showed that empirical H. pylori eradication
was the dominant strategy both in the Spanish and the US set-
tings. It was both cheaper and more effective in preventing recur-
rence of the bleeding ulcer.
Speciﬁcally, the 2-year rate of recurrent peptic ulcer bleeding
was lower for empirical H. pylori eradication strategy (6.1%)
than in “test for H. pylori and treatment, if positive” (7.4%),
“PPI maintenance” (11.1%), and “no preventive treatment”
(18.4%). Calculated overall mortality rates secondary to recur-
rent peptic ulcer bleeding per 1000 patients were 3.6, 4.5, 6.6,
and 11.1, respectively. Complete ICER and cost-effectiveness
mean values for all four strategies are shown in Table 1.
Sensitivity Analysis
One-way sensitivity analysis showed that none of the variables or
costs tested changed the main conclusions of the study. The most
inﬂuential variable was the prevalence of H. pylori in peptic ulcer
bleeding. In the high-cost area, when it fell below 45%, “empiri-
cal H. pylori eradication” strategy was no longer dominant.
Nevertheless, it remained cost-effective (ICER <€30,000) until
H. pylori prevalence in bleeding ulcer fell below 14%, when “PPI
maintenance” became the most cost-effective strategy.
By contrast, in the high-cost area, “empirical H. pylori eradi-
cation” was dominant until the prevalence of H. pylori in bleed-
ing peptic ulcer fell below 51%. It remained cost-effective (ICER
<$39,000) until prevalence fell below 28%. Below this value, the
“test for H. pylori and treatment, if positive” strategy became the
most cost-effective approach (ICER >$40,000).
The second most inﬂuential variable was losses to follow-up.
Although “empirical H. pylori eradication” remained the domi-
nant strategy, even assuming a zero percent rate of losses to
follow-up in any branch, the relative cost-effectiveness of
“empirical H. pylori eradication” strategy strongly increased as
losses to follow-up rose.
Monte Carlo multiple-way probabilistic analyses showed that
after 10,000 simulations, “empirical H. pylori eradication” was
the dominant strategy in 100% of the simulations for both low-
and high-cost areas.
Discussion
Our data strongly suggest that, under a wide range of conditions,
“empirical H. pylori eradication” is a dominant strategy—that is,
it is both cheaper and more effective—than all the remaining
strategies evaluated for curing H. pylori infection in patients with
peptic ulcer bleeding. In addition, this conclusion is fairly robust
and remains stable across the plausible variations of costs and
assumptions made in the study. Interestingly, despite higher costs,
and even assuming lower baseline H. pylori infection rates,
“empirical H. pylori eradication” strategy was nearly as effective
in the United States as in lower-cost areas.
“Empirical H. pylori eradication” strategy was more effective
because all patients with the infection were treated. Testing at
endoscopy and retesting negatives are nearly as effective, but a
very small percentage of false-negative patients (around 1%)
remain. In addition, the “empirical H. pylori eradication” strat-
egy avoids a number of visits and tests, thus compensating for the
cost of the extra treatments administered. Therefore, it remains
the dominant strategy, ahead of others such as the “test for
H. pylori and treatment, if positive”.
The inclusion of losses to follow-up is one of the strengths of
the present study. Although even assuming that no patients were
lost to follow-up, “empirical H. pylori eradication” remains the
most cost-effective strategy, the analysis suggests that if empirical
eradication truly improves compliance, the cost-effectiveness of
the strategy might be even higher than the estimates of this study
suggest. It may be especially effective in minorities or patients
with a socioeconomically depressed background, which make up
a large proportion of the losses to follow-up.
Limitations of the study include the fact that indirect costs
(mainly productivity losses) are not included in the analysis and
that the values assumed for losses to follow-up are largely hypo-
thetical. Second, the notion that immediate empirical treatment
improves compliance, although reasonable, needs to be con-
ﬁrmed in clinical practice. Finally, as the protective effects of
H. pylori eradication in bleeding are long lasting, a 2-year time
horizon probably underestimates the beneﬁts of eradication
strategies compared with non-eradication.
In conclusion, our study strongly suggests that “empirical H.
pylori eradication” strategy associated with PPI prophylaxis in
patients remaining on NSAID is the dominant strategy for pre-
venting recurrent peptic ulcer bleeding. The analysis is highly
robust and in the sensitivity analysis, the conclusions remain
unchanged even with extreme values of the key variables. The
results of the pharmacoeconomic model stress the need to
conﬁrm the effectiveness of the empirical eradication strategy by
clinical studies in patients with bleeding ulcer.
The authors are indebted to Michael Maudsley for his help with the
English grammar.
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